Lundbeck's Alzheimer drug delivers promising results  

A phase 3 study from cooperation partner Forest Labs shows good results for Lundbeck's Alzheimer drug Ebixa

Danish pharmaceutical company Lundbeck has announced that its drug for Alzheimer's disease, Ebixa (memantin), has shown promising results in a phase 3 study published by the company's US cooperation partner Forest Laboratories, Inc. Ebixa is the first in a new class of drugs for the treatment of Alzheimer's Disease, and is expected to fulfil unmet needs within this group of patients  - for whom no approved treatment has been available until now. On the basis of a recommendation from the Committee for Proprietary Medicinal Products (CPMP), the EU commission has issued a marketing authorisation for Ebixa covering all EEA countries. Ebixa has already been launched in Germany, Denmark and Mexico.

Lundbeck has licensed Ebixa from Merz Pharmaceuticals, a German research-based pharmaceutical company, and has acquired exclusive rights to a number of European countries as well as Canada, Australia and South Africa. Under a co-marketing agreement with Merz, Lundbeck has acquired semi-exclusive rights to the rest of the world, exclusive of USA and Japan. Lundbeck's partner Forest Laboratories, Inc holds the rights to the American market.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×